4.7 Article

A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling

Journal

JOURNAL OF EXPERIMENTAL MEDICINE
Volume 207, Issue 12, Pages 2569-2579

Publisher

ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20100857

Keywords

-

Funding

  1. Australian NHMRC [541951]
  2. National Institutes of Health [R01AI49993, P50CA097274, R01CA92153]
  3. Dept. of Veterans Affairs
  4. Lymphoma Research Foundation
  5. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development

Ask authors/readers for more resources

The cytokine B cell activating factor (BAFF) and its receptor, BAFF receptor (BAFF-R), modulate signaling cascades critical for B cell development and survival. We identified a novel mutation in TNFRSF13C, the gene encoding human BAFF-R, that is present in both tumor and germline tissue from a subset of patients with non-Hodgkin lymphoma. This mutation encodes a His159Tyr substitution in the cytoplasmic tail of BAFF-R adjacent to the TRAF3 binding motif. Signaling through this mutant BAFF-R results in increased NF-kappa B1 and NF-kappa B2 activity and increased immunoglobulin production compared with the wild-type (WT) BAFF-R. This correlates with increased TRAF2, TRAF3, and TRAF6 recruitment to His159Tyr BAFF-R. In addition, we document a requirement for TRAF6 in WT BAFF-R signaling. Together, these data identify a novel lymphoma-associated mutation in human BAFF-R that results in NF-kappa B activation and reveals TRAF6 as a necessary component of normal BAFF-R signaling.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available